Microba Life Sciences Limited (MAP.AX)
ASX - ASX Delayed price. Currency in AUD
Add to watchlist
As of 10:04AM AEST. Market open.
Loading interactive chart…
- Simply Wall St.
Positive Signs As Multiple Insiders Buy Microba Life Sciences Stock
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
- Simply Wall St.
Microba Life Sciences Full Year 2023 Earnings: Beats Expectations
Microba Life Sciences ( ASX:MAP ) Full Year 2023 Results Key Financial Results Revenue: AU$5.42m (up 16% from FY 2022...
- GlobeNewswire
Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update
ColoAlert® Revenue Increases 108% Year Over Year in the First Six Months of 2023 ColoFuture and eAArly Detect Studies on Track to Report Results in September and in Q4, 2023 BERKELEY, Calif. and MAINZ, Germany, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the results of the first six months and second quarter ending June 30, 2023 and provi
© 2024 Yahoo. All rights reserved.